1. Home
  2. TVTX vs ADEA Comparison

TVTX vs ADEA Comparison

Compare TVTX & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$42.68

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Adeia Inc.

ADEA

Adeia Inc.

HOLD

Current Price

$31.53

Market Cap

3.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
ADEA
Founded
N/A
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.3B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
TVTX
ADEA
Price
$42.68
$31.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
4
Target Price
$40.62
$31.00
AVG Volume (30 Days)
2.7M
1.7M
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
0.65%
EPS Growth
92.89
73.68
EPS
N/A
0.20
Revenue
N/A
$443,386,000.00
Revenue This Year
$44.76
N/A
Revenue Next Year
$35.51
$5.63
P/E Ratio
N/A
$161.15
Revenue Growth
N/A
17.91
52 Week Low
$13.88
$11.61
52 Week High
$48.61
$34.34

Technical Indicators

Market Signals
Indicator
TVTX
ADEA
Relative Strength Index (RSI) 62.11 58.78
Support Level $26.97 $16.07
Resistance Level $48.61 $34.34
Average True Range (ATR) 2.21 1.87
MACD -0.28 -0.19
Stochastic Oscillator 36.23 63.65

Price Performance

Historical Comparison
TVTX
ADEA

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About ADEA Adeia Inc.

Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.

Share on Social Networks: